Table 1.

Summary of demographic, autoimmune disease, cancer, treatment and outcomes data

Characteristics [n (%)]	Patients with PAD (n = 27)
Demographics
Age, years (mean, SD)	63.6 (11.5)
Male	14 (52)
Caucasian	26 (96)
Pre-existing autoimmune disease
Rheumatoid arthritis	8 (30)
Psoriasis/psoriatic arthritis	8 (30)*
Inflammatory bowel disease	4(15)*
Axial spondyloarthritis	3 (11)
Systemic lupus erythematosus	2 (7)
Polymyalgia rheumatica	1 (4)
Dermatomyositis	1 (4)*
Others	3 (11)
Cancer type
Lung	15 (56)
Melanoma	8 (30)
Other	4 (15)
Cancer stage
2	1 (4)
3	1 (4)
4	25 (93)
Cancer therapy
Pembrolizumab	20 (74)
Nivolumab	7 (26)
Ipilimumab	2 (7)*
Duration of ICI therapy, months (median, IQR)	4.0 (2.0–9.0)
Immune-related adverse events
No irAE	6 (22)
Any irAE	21 (78)
Flares	14 (52)
New irAE	14 (52)
New rheumatic irAE	10 (37)
New other irAE	6 (22)
CTCAE grade (PAD flares; new irAEs)
1 (asymptomatic/mild)	4 (15); 3 (11)
2 (moderate)	8 (30); 6 (22)
3 (severe)	2 (7); 4 (15)
4 (life-threatening)	0; 1 (4)
Time to flare, months (median, IQR)	< 1 (< 1–2)
Treatment for irAE (for PAD flare; for new irAE)
Prednisone > 10 mg daily	8 (30); 10 (37)
Immunosuppressive drugs	7 (26); 9 (33)
Biologic drug	1 (4); 0
ICI discontinuation (due to PAD flare; due to new irAE)	2 (7); 8 (30)
Tumor response to ICI therapy*
Complete response	4 (15)
Partial responses	10 (37)
Stabilization	1 (4)
Progression	11 (41)
Follow-up time, months (median, IQR)	11.0 (6.0–17.5)

ICI immune checkpoint inhibitor; irAE immune-related adverse event; PAD preexisting autoimmune disease

*Three patients had two pre-existing autoimmune diseases. All psoriatic arthritis patients had psoriasis. One patient received ipilimumab followed by pembrolizumab, and one patient received pembrolizumab followed by ipilimumab. Eleven patients had more than 1 irAE. Data on tumor response were missing in 1 patient